0001753926-24-000314.txt : 20240215 0001753926-24-000314.hdr.sgml : 20240215 20240215200249 ACCESSION NUMBER: 0001753926-24-000314 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240215 FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Davis Todd C CENTRAL INDEX KEY: 0001392029 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 24645503 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Chromocell Therapeutics Corp CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 863335449 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 BUSINESS PHONE: 9176446313 MAIL ADDRESS: STREET 1: 685 US HIGHWAY ONE CITY: NORTH BRUNSWICK STATE: NJ ZIP: 08902 3 1 ownership.xml X0206 3 2024-02-15 0 0001919246 Chromocell Therapeutics Corp CHRO 0001392029 Davis Todd C C/O CHROMOCELL THERAPEUTICS CORPORATION 4400 ROUTE 9 SOUTH, SUITE 1000 FREEHOLD NJ 07728 1 0 0 0 Promissory Note 2023-12-31 Common Stock 175000 D Stock Options 22.68 2033-01-10 Common Stock 33334 D Stock Options 22.68 2033-01-10 Common Stock 22223 D The Reporting Person holds a promissory note with a face amount of $175,000 and purchase price of $100,000, which provides the Reporting Person the right but not the obligation, to purchase securities offered in the Issuer's initial public offering by presenting the promissory note in whole or in part to purchase such securities as legal tender therefor on a dollar-for-dollar basis based upon the offering price of such securities to the public. The promissory note bears no interest except in the case of certain events of default. On January 10, 2023, the Reporting Person was granted stock options to purchase 33,334 shares of common stock at an exercise price of $22.68 per share. 3,334 shares of such options became exercisable on April 10, 2023, 3,334 shares of such options became exercisable on July 10, 2023, 3,334 shares of such options became exercisable on October 10, 2023, 3,334 shares of such options became exercisable on January 10, 2024, 3,334 shares of such options will become exercisable on April 10, 2024 and the remaining 16,664 shares of such options shall become exercisable in equal installments on a quarterly basis, subject to the Reporting Person's continued service to Issuer. The final installment shall become exercisable on July 10, 2025, subject to the Reporting Person's continued service to Issuer. On January 10, 2023, the Reporting Person was granted stock options to purchase 22,223 shares of common stock at an exercise price of $22.68 per share which shall become exercisable upon Issuer's establishment of a second clinical program, subject to the Reporting Person's continued service to Issuer. Exhibit 24 - Power of Attorney /s/ Todd Davis 2024-02-15 EX-24 2 g084046_ex24.htm POWER OF ATTORNEY

Exhibit 24

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENT, that the undersigned hereby constitutes and appoints Aaron M. Schleicher, Esq. and Chuanyang Jiang, Esq. of the law firm Sullivan & Worcester LLP and Francis Knuettel II, individually and not jointly, as the undersigned’s true and lawful attorneys-in-fact to:

(1)             prepare, execute in the undersigned’s name and on the undersigned’s behalf, and submit to the U.S. Securities and Exchange Commission (the “SEC”) an Application for EDGAR Access (Form ID), including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the “Act”), or any rule or regulation of the SEC;

(2)             execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or director of Chromocell Therapeutics Corporation (the “Company”), any and all Forms 3, 4 and 5 required to be filed by the undersigned in accordance with Section 16(a) of the Act and the rules thereunder;

(3)             do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and

(4)             take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorney-in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming, nor is the Company hereby assuming, any of the undersigned’s responsibilities to comply with Section 16 of the Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of August, 2023.

    /s/ Todd C. Davis
    Todd C. Davis